Cargando…

Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model

BACKGROUND AND OBJECTIVES: We sought to investigate an anti-atherosclerotic and anti-inflammatory effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in normoglycemic atherosclerotic rabbit model. METHODS: Male New Zealand white rabbits (n=26) were fed with a 1% high-cholesterol diet for 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Seul-Gee, Lee, Seung-Jun, Lee, Jung-Jae, Kim, Jung-Sun, Lee, Oh-Hyun, Kim, Choong-Ki, Kim, Darae, Lee, Yong-Ho, Oh, Jaewon, Park, Seil, Jeon, Ok-Hee, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, Jang, Yangsoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098824/
https://www.ncbi.nlm.nih.gov/pubmed/32153145
http://dx.doi.org/10.4070/kcj.2019.0296
_version_ 1783511231637749760
author Lee, Seul-Gee
Lee, Seung-Jun
Lee, Jung-Jae
Kim, Jung-Sun
Lee, Oh-Hyun
Kim, Choong-Ki
Kim, Darae
Lee, Yong-Ho
Oh, Jaewon
Park, Seil
Jeon, Ok-Hee
Hong, Sung-Jin
Ahn, Chul-Min
Kim, Byeong-Keuk
Ko, Young-Guk
Choi, Donghoon
Hong, Myeong-Ki
Jang, Yangsoo
author_facet Lee, Seul-Gee
Lee, Seung-Jun
Lee, Jung-Jae
Kim, Jung-Sun
Lee, Oh-Hyun
Kim, Choong-Ki
Kim, Darae
Lee, Yong-Ho
Oh, Jaewon
Park, Seil
Jeon, Ok-Hee
Hong, Sung-Jin
Ahn, Chul-Min
Kim, Byeong-Keuk
Ko, Young-Guk
Choi, Donghoon
Hong, Myeong-Ki
Jang, Yangsoo
author_sort Lee, Seul-Gee
collection PubMed
description BACKGROUND AND OBJECTIVES: We sought to investigate an anti-atherosclerotic and anti-inflammatory effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in normoglycemic atherosclerotic rabbit model. METHODS: Male New Zealand white rabbits (n=26) were fed with a 1% high-cholesterol diet for 7 weeks followed by normal diet for 2 weeks. After balloon catheter injury, the rabbits were administered with the Dapagliflozin (1mg/kg/day) or control-medium for 8 weeks (n=13 for each group). All lesions were assessed with angiography, optical coherence tomography (OCT), and histological assessment. RESULTS: Atheroma burden (38.51±3.16% vs. 21.91±1.22%, p<0.01) and lipid accumulation (18.90±3.63% vs. 10.20±2.03%, p=0.047) was significantly decreased by SGLT-2 inhibitor treatment. The SGLT-2 inhibitor group showed lower macrophage infiltration (20.23±1.89% vs. 12.72±1.95%, p=0.01) as well as tumor necrosis factor (TNF)-α expression (31.17±4.40% vs. 19.47±2.10%, p=0.025). Relative area of inducible nitric oxide synthase(+) macrophages was tended to be lower in the SGLT-2 inhibitor-treated group (1.00±0.16% vs. 0.71±0.10%, p=0.13), while relative proportion of Arg1(+) macrophage was markedly increased (1.00±0.27% vs. 2.43±0.64%, p=0.04). As a result, progression of atherosclerosis was markedly attenuated in SGLT-2 inhibitor treated group (OCT area stenosis, 32.13±1.20% vs. 22.77±0.88%, p<0.01). Mechanistically, SGLT-2 treatment mitigated the inflammatory responses in macrophage. Especially, Toll-like receptor 4/nuclear factor-kappa B signaling pathway, and their downstream effectors such as interleukin-6 and TNF-α were markedly suppressed by SGLT-2 inhibitor treatment. CONCLUSIONS: These results together suggest that SGLT-2 inhibitor exerts an anti-atherosclerotic effect through favorable modulation of inflammatory response as well as macrophage characteristics in non-diabetic situation.
format Online
Article
Text
id pubmed-7098824
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Society of Cardiology
record_format MEDLINE/PubMed
spelling pubmed-70988242020-05-01 Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model Lee, Seul-Gee Lee, Seung-Jun Lee, Jung-Jae Kim, Jung-Sun Lee, Oh-Hyun Kim, Choong-Ki Kim, Darae Lee, Yong-Ho Oh, Jaewon Park, Seil Jeon, Ok-Hee Hong, Sung-Jin Ahn, Chul-Min Kim, Byeong-Keuk Ko, Young-Guk Choi, Donghoon Hong, Myeong-Ki Jang, Yangsoo Korean Circ J Original Article BACKGROUND AND OBJECTIVES: We sought to investigate an anti-atherosclerotic and anti-inflammatory effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in normoglycemic atherosclerotic rabbit model. METHODS: Male New Zealand white rabbits (n=26) were fed with a 1% high-cholesterol diet for 7 weeks followed by normal diet for 2 weeks. After balloon catheter injury, the rabbits were administered with the Dapagliflozin (1mg/kg/day) or control-medium for 8 weeks (n=13 for each group). All lesions were assessed with angiography, optical coherence tomography (OCT), and histological assessment. RESULTS: Atheroma burden (38.51±3.16% vs. 21.91±1.22%, p<0.01) and lipid accumulation (18.90±3.63% vs. 10.20±2.03%, p=0.047) was significantly decreased by SGLT-2 inhibitor treatment. The SGLT-2 inhibitor group showed lower macrophage infiltration (20.23±1.89% vs. 12.72±1.95%, p=0.01) as well as tumor necrosis factor (TNF)-α expression (31.17±4.40% vs. 19.47±2.10%, p=0.025). Relative area of inducible nitric oxide synthase(+) macrophages was tended to be lower in the SGLT-2 inhibitor-treated group (1.00±0.16% vs. 0.71±0.10%, p=0.13), while relative proportion of Arg1(+) macrophage was markedly increased (1.00±0.27% vs. 2.43±0.64%, p=0.04). As a result, progression of atherosclerosis was markedly attenuated in SGLT-2 inhibitor treated group (OCT area stenosis, 32.13±1.20% vs. 22.77±0.88%, p<0.01). Mechanistically, SGLT-2 treatment mitigated the inflammatory responses in macrophage. Especially, Toll-like receptor 4/nuclear factor-kappa B signaling pathway, and their downstream effectors such as interleukin-6 and TNF-α were markedly suppressed by SGLT-2 inhibitor treatment. CONCLUSIONS: These results together suggest that SGLT-2 inhibitor exerts an anti-atherosclerotic effect through favorable modulation of inflammatory response as well as macrophage characteristics in non-diabetic situation. The Korean Society of Cardiology 2020-02-12 /pmc/articles/PMC7098824/ /pubmed/32153145 http://dx.doi.org/10.4070/kcj.2019.0296 Text en Copyright © 2020. The Korean Society of Cardiology https://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Seul-Gee
Lee, Seung-Jun
Lee, Jung-Jae
Kim, Jung-Sun
Lee, Oh-Hyun
Kim, Choong-Ki
Kim, Darae
Lee, Yong-Ho
Oh, Jaewon
Park, Seil
Jeon, Ok-Hee
Hong, Sung-Jin
Ahn, Chul-Min
Kim, Byeong-Keuk
Ko, Young-Guk
Choi, Donghoon
Hong, Myeong-Ki
Jang, Yangsoo
Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
title Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
title_full Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
title_fullStr Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
title_full_unstemmed Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
title_short Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
title_sort anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (sglt-2) inhibitor in a normoglycemic rabbit model
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098824/
https://www.ncbi.nlm.nih.gov/pubmed/32153145
http://dx.doi.org/10.4070/kcj.2019.0296
work_keys_str_mv AT leeseulgee antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT leeseungjun antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT leejungjae antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT kimjungsun antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT leeohhyun antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT kimchoongki antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT kimdarae antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT leeyongho antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT ohjaewon antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT parkseil antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT jeonokhee antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT hongsungjin antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT ahnchulmin antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT kimbyeongkeuk antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT koyoungguk antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT choidonghoon antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT hongmyeongki antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel
AT jangyangsoo antiinflammatoryeffectforatherosclerosisprogressionbysodiumglucosecotransporter2sglt2inhibitorinanormoglycemicrabbitmodel